Search

Genmab A-S

Închisă

2,149 1.7

Rezumat

Modificarea prețului

24h

Curent

Minim

2103

Maxim

2132

Indicatori cheie

By Trading Economics

Venit

243M

295M

Vânzări

259M

1.2B

P/E

Medie Sector

24.245

57.002

EPS

34.85

Marjă de profit

25.541

Angajați

3,119

EBITDA

216M

431M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

-1.49% downside

Dividende

By Acuity

Următoarele câștiguri

5 nov. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

11B

124B

Deschiderea anterioară

2147.3

Închiderea anterioară

2149

Genmab A-S Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

17 aug. 2026, 23:57 UTC

Ambarella shares declined during after-market hours amid broader geopolitical concerns affecting market sentiment. The stock remained above its 20-day moving average.

17 aug. 2026, 23:56 UTC

Correlated Moves

Energy Fuels Inc. shares rose in after-market trading amid positive sentiment in the energy sector and rising crude oil prices due to geopolitical tensions.

17 aug. 2026, 23:56 UTC

Insteel Industries Inc shares are lower in after-market hours, following a slight decline after Monday's close amid broader market geopolitical concerns.

17 aug. 2026, 23:56 UTC

Correlated Moves

Valley National Bancorp shares are trading higher in after-market hours, reflecting stability as they remain near the upper end of their one-month range.

17 aug. 2026, 23:56 UTC

Shares of Aquestive Therapeutics Inc. are trading higher in after-market hours, remaining significantly above their 20-day moving average. No specific news was identified.

17 aug. 2026, 23:56 UTC

Social Media

Immunovant shares are higher in after-market trading, driven by positive sentiment around the product pipeline for IMVT-1402 and comparisons to ARGX's success.

17 aug. 2026, 23:56 UTC

Geron Corp shares are higher in after-market trading, reflecting notable strength. The stock is significantly above its 20-day moving average.

17 aug. 2026, 23:56 UTC

Brown & Brown Inc. shares are trading lower in after-market hours, continuing a trend of three consecutive sessions finishing lower and remaining below the 20-day moving average.

17 aug. 2026, 23:56 UTC

iHeartMedia Inc shares are higher in after-market trading, recovering from earlier declines amid geopolitical concerns and rising crude oil prices.

17 aug. 2026, 23:56 UTC

Clean Harbors Inc. shares are higher in after-market trading, reflecting a modest gain since Monday's close amid rising crude oil prices and geopolitical tensions.

17 aug. 2026, 23:56 UTC

ETF Constituents
Correlated Moves
Macro News

Boston Properties announced a $700 million public offering of senior unsecured notes due in 2036, funding existing debt repayment. VNQ remains roughly flat in after-market trading.

17 aug. 2026, 23:56 UTC

Mondelez International Inc. is seeing modest gains in after-market trading. Broader market dynamics have influenced trading activity today, but no specific news was identified.

17 aug. 2026, 23:56 UTC

Correlated Moves

Eastman Chemical Co shares are lower in after-market hours amid market volatility and rising crude oil prices, influenced by geopolitical tensions in the Middle East.

17 aug. 2026, 23:56 UTC

Oil States International shares rise in after-market hours, supported by increasing Brent crude prices, which reached $90.68 amid Middle East geopolitical tensions.

17 aug. 2026, 23:56 UTC

Sabre Corp shares are lower in after-market trading, amid notable volatility and broader market concerns over escalating geopolitical tensions and rising crude oil prices.

17 aug. 2026, 23:56 UTC

Correlated Moves

Northern Oil and Gas Inc remains roughly flat in after-market trading amid geopolitical concerns affecting oil prices, which saw a slight uptick.

17 aug. 2026, 23:56 UTC

News
Social Media

Axon Enterprise shares are lower in after-market hours, following a report highlighting high valuations and recent military contracts from Bulgaria.

17 aug. 2026, 23:56 UTC

Accuray Inc shares are lower in after-market trading amid broader market fluctuations and geopolitical concerns, though they remain above their 20-day moving average.

17 aug. 2026, 23:56 UTC

United Airlines shares advanced in after-market trading, reflecting a modest rise despite geopolitical concerns and rising crude oil prices impacting operational costs.

17 aug. 2026, 23:56 UTC

Correlated Moves

Flowers Foods Inc remains roughly flat in after-market trading amid broader market movements influenced by escalating geopolitical tensions in the Middle East.

17 aug. 2026, 23:56 UTC

Transocean Ltd shares are higher in after-market trading, supported by rising crude oil prices amid geopolitical tensions affecting shipping routes.

17 aug. 2026, 23:56 UTC

News

Warner Bros Discovery shares are lower in after-market trading amid ongoing litigation over its merger with Paramount, which faces a $1.9 billion bond request.

17 aug. 2026, 23:56 UTC

News

Allstate Corp shares are lower in after-market hours amid broader market weakness. Geopolitical concerns are affecting trading sentiment despite recent positive earnings highlights.

17 aug. 2026, 23:56 UTC

Williams Companies shares are higher in after-market trading, supported by rising crude oil prices amid geopolitical tensions in the Middle East.

17 aug. 2026, 23:56 UTC

News

Replimune Group Inc shares are lower in after-market hours amid negative sentiment from multiple class action lawsuits alleging securities fraud and misleading statements.

17 aug. 2026, 23:56 UTC

Albany International shares declined in after-market hours amid broader market weakness. The stock remains below its 20-day moving average and near its one-month low.

17 aug. 2026, 23:56 UTC

Array Technologies shares are higher in after-market hours, despite trading below their 20-day moving average amid broader market dynamics and geopolitical tensions.

17 aug. 2026, 23:56 UTC

Correlated Moves
Macro News

Crude oil prices increased amid escalating tensions in the Middle East, influencing broader market volatility. The US 30Y Treasury Bond Index is trading slightly higher.

17 aug. 2026, 23:52 UTC

Fifth Third Bancorp shares are lower in after-market trading amid rising geopolitical tensions and increasing crude oil prices, with no specific company news identified.

17 aug. 2026, 23:52 UTC

Australia's Consumer Confidence Data Release Set for August 18 Amidst Fragile Economic Sentiment and High Inflation Concerns.

Comparație

Modificare preț

Genmab A-S Așteptări

Obiectiv de preț

By TipRanks

-1.49% jos

Prognoză pe 12 luni

Medie 2,493.35 DKK  -1.49%

Maxim 3,320 DKK

Minim 308.417 DKK

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruGenmab A-S - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

7 ratings

3

Cumpărare

2

Păstrare

2

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
help-icon Live chat